Itraconazole Patent Expiration
Itraconazole was first introduced by Janssen Pharmaceuticals Inc
Itraconazole Patents
Given below is the list of patents protecting Itraconazole, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tolsura | US10463740 | Itraconazole compositions and dosage forms, and methods of using the same | Jun 21, 2033 | Mayne Pharma |
| Tolsura | US10806792 | Itraconazole compositions and dosage forms, and methods of using the same | Jun 21, 2033 | Mayne Pharma |
| Tolsura | US8921374 | Itraconazole compositions and dosage forms, and methods of using the same | Jun 21, 2033 | Mayne Pharma |
| Tolsura | US9272046 | Itraconazole compositions and dosage forms, and methods of using the same | Jun 21, 2033 | Mayne Pharma |
| Tolsura | US9713642 | Itraconazole compositions and dosage forms, and methods of using the same | Jun 21, 2033 | Mayne Pharma |
| Onmel | US8486456 | Itraconazole compositions with improved bioavailability | Oct 03, 2028 | Sebela Ireland Ltd |
| Tolsura | US8771739 | Pharmaceutical compositions for poorly soluble drugs |
Jul 25, 2023
(Expired) | Mayne Pharma |
| Sporanox | US6407079 | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
Jun 18, 2019
(Expired) | Janssen Pharms |
| Onmel | US6509038 | Antifungal compositions with improved bioavailability |
May 12, 2017
(Expired) | Sebela Ireland Ltd |
| Onmel | US7081255 | Antifungal compositions with improved bioavailability |
May 12, 2017
(Expired) | Sebela Ireland Ltd |
| Onmel | US8591948 | Antifungal compositions with improved bioavailability |
May 12, 2017
(Expired) | Sebela Ireland Ltd |
| Sporanox | US5707975 | Oral formulations on an antifungal |
Jan 13, 2015
(Expired) | Janssen Pharms |
| Sporanox | US5633015 | Beads having a core coated with an antifungal and a polymer |
May 27, 2014
(Expired) | Janssen Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Itraconazole's patents.
Latest Legal Activities on Itraconazole's Patents
Given below is the list recent legal activities going on the following patents of Itraconazole.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Jan, 2026 | US8771739 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Jan, 2025 | US9713642 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Apr, 2024 | US10806792 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Aug, 2023 | US9272046 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 04 Apr, 2023 | US10463740 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 May, 2022 | US8921374 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 28 Apr, 2022 | US8921374 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 Dec, 2021 | US8771739 |
| Recordation of Patent Grant Mailed Critical
| 20 Oct, 2020 | US10806792 |
| Patent Issue Date Used in PTA Calculation Critical
| 20 Oct, 2020 | US10806792 |
About Veterinary Itraconazole
Itraconazole is used in a drug marketed by 1 company: Virbac Ah Inc.
Other drugs containing Itraconazole are: Itrafungol .
Itraconazole's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Itraconazole:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
